JP2019524687A5 - - Google Patents

Download PDF

Info

Publication number
JP2019524687A5
JP2019524687A5 JP2018568875A JP2018568875A JP2019524687A5 JP 2019524687 A5 JP2019524687 A5 JP 2019524687A5 JP 2018568875 A JP2018568875 A JP 2018568875A JP 2018568875 A JP2018568875 A JP 2018568875A JP 2019524687 A5 JP2019524687 A5 JP 2019524687A5
Authority
JP
Japan
Prior art keywords
antibody
drug conjugate
hiv
drug
antibody drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018568875A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524687A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/053979 external-priority patent/WO2018002902A1/en
Publication of JP2019524687A publication Critical patent/JP2019524687A/ja
Publication of JP2019524687A5 publication Critical patent/JP2019524687A5/ja
Withdrawn legal-status Critical Current

Links

JP2018568875A 2016-07-01 2017-06-30 抗体薬物複合体およびこれを用いた治療方法 Withdrawn JP2019524687A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662357410P 2016-07-01 2016-07-01
US62/357,410 2016-07-01
PCT/IB2017/053979 WO2018002902A1 (en) 2016-07-01 2017-06-30 Antibody-drug conjugates and therapeutic methods using the same

Publications (2)

Publication Number Publication Date
JP2019524687A JP2019524687A (ja) 2019-09-05
JP2019524687A5 true JP2019524687A5 (cg-RX-API-DMAC7.html) 2020-08-13

Family

ID=59399452

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018568875A Withdrawn JP2019524687A (ja) 2016-07-01 2017-06-30 抗体薬物複合体およびこれを用いた治療方法

Country Status (5)

Country Link
US (1) US20190328900A1 (cg-RX-API-DMAC7.html)
EP (1) EP3478324A1 (cg-RX-API-DMAC7.html)
JP (1) JP2019524687A (cg-RX-API-DMAC7.html)
TW (1) TW201811376A (cg-RX-API-DMAC7.html)
WO (1) WO2018002902A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112638426B (zh) * 2018-09-21 2023-06-16 中国人民解放军军事科学院军事医学研究院 基于芳硝基的连接子、含连接子的抗体偶联药物及连接子的用途
JP2022519586A (ja) * 2019-02-04 2022-03-24 ゼネティック バイオサイエンシーズ インコーポレイテッド 糖ポリシアル酸化治療用タンパク質を使用する方法
TW202104274A (zh) * 2019-04-09 2021-02-01 法商賽諾菲公司 用於治療hiv感染之三特異性及/或三價結合蛋白
US20240124561A1 (en) * 2019-10-17 2024-04-18 Minicircle Inc. Nucleic acids encoding hiv neutralizing antibodies and uses thereof
IL293566A (en) * 2019-12-09 2022-08-01 Viiv Healthcare Co Pharmaceutical preparations containing Cabotgravir
JP2024500322A (ja) * 2020-12-07 2024-01-09 ヴィーブ、ヘルスケア、カンパニー 併用療法
IL307498A (en) 2021-04-05 2023-12-01 Altheia Science S R L Diagnosis and treatment of myeloid disorders and acute leukemia using antigens specific to new tumors
CN115590976B (zh) * 2021-06-28 2025-06-27 前沿生物药业(南京)股份有限公司 治疗和/或预防hiv相关疾病的apc偶联物及其制法和应用
CN115590965B (zh) * 2021-06-28 2024-06-28 前沿生物药业(南京)股份有限公司 用于治疗和/或预防hiv相关疾病的aptc偶联物及其应用
IL313306A (en) * 2021-12-17 2024-08-01 Viiv Healthcare Co Combined treatments for HIV infections and their uses
WO2023194501A1 (en) 2022-04-05 2023-10-12 Altheia Science S.R.L. Treatment of myeloid disorders and acute leukemias targeting novel tumor specific antigens
WO2024245401A1 (en) * 2023-06-01 2024-12-05 Taimed Biologics Inc. Antibody-drug conjugates for treating infections of human immunodeficiency virus (hiv)
CN117138104A (zh) * 2023-09-18 2023-12-01 潍坊医学院附属医院 一种用于烧伤创面的抗氧化蛋白肽基纳米水凝胶
WO2025249542A1 (ja) * 2024-05-31 2025-12-04 国立大学法人東京科学大学 抗hiv抗体薬物複合体

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
CN1192688A (zh) 1995-06-07 1998-09-09 特莱默里斯公司 联合疗法治疗hiv和其它病毒性感染
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
WO2002074769A1 (en) 2001-03-19 2002-09-26 Ono Pharmaceutical Co., Ltd. Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
US9005889B2 (en) 2007-01-16 2015-04-14 The Johns Hopkins University Synergistic antiviral compositions comprising a viral attachment inhibitor, integration inhibitor, and proviral transcription inhibitor
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
US7985557B2 (en) 2007-05-23 2011-07-26 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
UA108598C2 (xx) 2008-04-30 2015-05-25 Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
ES2560807T3 (es) 2008-07-21 2016-02-22 Polytherics Limited Nuevos reactivos y procedimiento de conjugación de moléculas biológicas
DK2889624T3 (en) 2009-08-10 2018-12-10 Ucl Business Plc Reversible covalent bonding of functional molecules
AU2010292172A1 (en) 2009-09-09 2012-05-03 Centrose, Llc Extracellular targeted drug conjugates
US9175070B2 (en) 2009-09-25 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
WO2011046623A2 (en) 2009-10-16 2011-04-21 Duke University Hiv-1 antibodies
EP2515914A4 (en) * 2009-12-23 2013-09-11 Scripps Research Inst BIOCONJUGATION OF TYROSINE BY EYE REACTIONS IN AQUEOUS MEDIA
PT2528625E (pt) 2010-04-15 2013-10-17 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
WO2012040562A2 (en) 2010-09-24 2012-03-29 International Aids Vaccine Initiative Novel hiv-1 broadly neutralizing antibodies
EP2635300A4 (en) * 2010-11-03 2014-04-02 Ibc Pharmaceuticals Inc DOCK-AND-LOCK (DNL) CONSTRUCTS FOR THERAPY AGAINST HUMAN IMMUNE WEAKAGE VIRUS (HIV)
CN103282385A (zh) 2010-11-12 2013-09-04 美国洛克菲勒大学 用于hiv治疗的融合蛋白
WO2012106578A1 (en) 2011-02-04 2012-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc)
DK2714685T3 (en) 2011-05-27 2017-01-09 Ambrx Inc FORMATIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID BOUND dolastatin
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
EP2753644A1 (en) 2011-09-09 2014-07-16 Universiteit Utrecht Holding B.V. Broadly neutralizing vhh against hiv-1
AU2012322934B2 (en) 2011-10-14 2016-09-08 Medimmune Limited Pyrrolobenzodiazepines
CA2850375C (en) 2011-10-14 2019-07-02 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
JP6166728B2 (ja) 2011-10-14 2017-07-19 メドイミューン・リミテッドMedImmune Limited ピロロベンゾジアゼピンの製造に有用な合成方法及び中間体
CA2850373C (en) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
CN104080805B (zh) 2011-11-07 2017-02-22 美国政府健康及人类服务部 gp41中和性抗体及其用途
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
BR112014013526A8 (pt) 2011-12-05 2017-06-13 Igenica Biotherapeutics Inc conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
CN104271597B (zh) 2011-12-08 2018-05-25 美国政府(由卫生和人类服务部的部长所代表) Hiv-1的中和抗体及其用途
PT2908912T (pt) 2012-10-18 2020-09-04 Univ Rockefeller Anticorpos anti-hiv amplamente neutralizantes
HRP20180268T4 (hr) 2012-10-23 2026-03-27 Synaffix B.V. Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu
EP2765138B1 (en) 2012-11-05 2018-01-10 International Aids Vaccine Initiative HIV-1 envelope glycoprotein
US10058603B2 (en) 2013-03-15 2018-08-28 Glaxosmithkline Biologicals S.A. Vaccine
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗-prlr抗體及其用途
EP3077051B1 (en) 2013-12-02 2023-04-12 The Trustees of Columbia University in the City of New York Improved hiv-1-neutralizing antibody potency and breadth via cell receptor anchoring using bispecific antibodies with native architecture
US10093720B2 (en) 2014-06-11 2018-10-09 International Aids Vaccine Initiative Broadly neutralizing antibody and uses thereof
WO2016196975A1 (en) 2015-06-03 2016-12-08 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Neutralizing antibodies to hiv-1 env and their use
EP4011911A1 (en) 2015-11-03 2022-06-15 The United States of America as represented by The Secretary Department of Health and Human Services Neutralizing antibodies to hiv-1 gp41 and their use

Similar Documents

Publication Publication Date Title
Root et al. HIV-1 gp41 as a target for viral entry inhibition
JP2022512478A5 (cg-RX-API-DMAC7.html)
JP2019172710A5 (cg-RX-API-DMAC7.html)
JP2017537893A5 (cg-RX-API-DMAC7.html)
Stoddart et al. Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice
WO2001043779A3 (en) Anti-hiv-1 conjugates for treatment of hiv disease
JP2022513223A5 (cg-RX-API-DMAC7.html)
JPWO2022102695A5 (cg-RX-API-DMAC7.html)
EP4378958A3 (en) High-affinity anti-mertk antibodies and uses thereof
WO2007134037A3 (en) Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
McGaughey et al. Progress towards the development of a HIV-1 gp41-directed vaccine
CA2794632A1 (en) Bifunctional molecules for inactivating hiv and blocking hiv entry
Wang et al. Inhibition of HIV virus by neutralizing Vhh attached to dual functional liposomes encapsulating dapivirine
Ashkenazi et al. Insights into the mechanism of HIV-1 envelope induced membrane fusion as revealed by its inhibitory peptides
Pu et al. Peptide-based HIV entry inhibitors
WO2011008863A4 (en) Stereoisomer peptides and their polymer conjugates for hiv disease
Lagenaur et al. sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates
Chang et al. A novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitro
US9114107B2 (en) Compositions for inhibiting virus entry and promoting virolysis, and methods thereof
US20150011483A1 (en) Inhibition of HIV-1 Infection by Potent Metallocene Conjugated Peptide Through Conformational Entrapment of Envelope GP120
Su et al. Virus entry inhibitors: past, present, and future
WO2012061548A1 (en) Dock-and-lock (dnl) constructs for human immunodeficiency virus (hiv) therapy
GB2471692A (en) HIV gp41-binding single-chain coiled-coil peptide comprising heptad repeats
WO2022125378A8 (en) Combination therapy
Kobayakawa et al. Bivalent HIV-1 fusion inhibitors based on peptidomimetics